Mirae Asset Global Etfs Holdings Ltd. Avidity Biosciences, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $41.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 179,490 shares of RNA stock, worth $5.19 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
179,490
Previous 184,041
2.47%
Holding current value
$5.19 Million
Previous $7.52 Million
9.64%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding RNA
# of Institutions
253Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$308 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$267 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$249 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$235 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$203 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.51B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...